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Abstract 
Pulmonary hypertension is a well-known though poorly characterized disease in 
veterinary medicine. In humans, pulmonary veno-occlusive disease (PVOD) is a rare 
cause of severe pulmonary hypertension with a mean survival time of 2 years 
without lung transplantation. Eleven adult dogs (5 males, 6 females; median age 
10.5 years, representing various breeds) were examined following the development 
of severe respiratory signs. Lungs of affected animals were evaluated 
morphologically and with immunohistochemistry for alpha smooth muscle actin, 
desmin, CD31, CD3, CD20, and CD204. All dogs had pulmonary lesions consistent 
with PVOD, consisting of occlusive remodeling of small- to medium-sized pulmonary 
veins, foci of pulmonary capillary hemangiomatosis (PCH), and accumulation of 
hemosiderophages; 6 of 11 dogs had substantial pulmonary arterial medial and 
intimal thickening. Ultrastructural examination and immunohistochemistry showed 
that smooth muscle cells contributed to the venous occlusion. Increased expression 
of CD31 was evident in regions of PCH indicating increased numbers of endothelial 
cells in these foci. Spindle cells strongly expressing alpha smooth muscle actin and 
desmin co-localized with foci of PCH; similar cells were present but less intensely 
labeled elsewhere in non-PCH alveoli. B cells and macrophages, detected by 
immunohistochemistry, were not co-localized with the venous lesions of canine 
PVOD; small numbers of CD3-positive T cells were occasionally in and around the 
wall of remodeled veins. These findings indicate a condition in dogs with clinically 
severe respiratory disease and pathologic features resembling human PVOD, 
including foci of pulmonary venous remodeling and PCH.
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Introduction 
Pulmonary hypertension is a clinical diagnosis established through the 
documentation of pulmonary arterial (PA) pressures above established normal 
values. In human medicine, the first efforts to classify pulmonary hypertension (PH) 
subdivided the disease into 2 categories—primary or secondary—based on whether 
or not an underlying disease could be identified as the cause of the PH (secondary 
PH).[42] Pulmonary hypertension in humans is now subdivided into 5 categories: (1) 
pulmonary arterial hypertension (so-called primary PH), (2) pulmonary venous 
hypertension (PVH), (3) pulmonary hypertension associated with underlying lung 
disorders or hypoxemia, (4) pulmonary hypertension caused by chronic 
thromboembolic/embolic lung disease, and (5) pulmonary hypertension caused by 
miscellaneous disorders affecting the pulmonary vasculature, for example, 
schistosomiasis, sarcoidosis, or alveolar remodeling associated with capillary 
hemangiomatosis.[8] Importantly, for the purposes of this study, pulmonary veno-
occlusive disease (PVOD) is recognized as a distinct cause of pulmonary venous 
hypertension whose clinical expression is one of severe pulmonary arterial 
hypertension (PAH).[8] 
Pulmonary veno-occlusive disease is a rare severe form of PAH in humans; the 
incidence of disease has been estimated at .1 to .2 cases per million individuals, 
accounting for roughly 10% of the cases of idiopathic PAH diagnosed in people.[19] 
PVOD has been diagnosed in a wide age range, from infants to adults, with some 
reports suggesting a higher frequency in children.[22,43,47] Clinically, PVOD can be 
difficult to distinguish from other severe forms of PAH. Documentation of PH with 
radiographic evidence consistent with pulmonary edema in the face of normal left 
atrial and pulmonary arterial wedge pressures—both ruling out left-sided heart failure 
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as a cause—is highly suggestive of a diagnosis of PVOD.[20,24] PVOD tends to be 
much more clinically severe than most other forms of PAH, with an average survival 
time of 2 years following diagnosis.[19,28] 
The severity of the clinical disease reflects the vascular remodeling characteristic of 
PVOD and its predicted impact on pulmonary blood flow. As the name suggests, the 
disease is characterized by occlusive remodeling of pulmonary veins. This 
remodeling primarily affects small pulmonary veins and venules leading to upstream 
alveolar capillary congestion and engorgement and accumulation of 
hemosiderophages. In addition to the veno-occlusive remodeling, a second lesion 
known as pulmonary capillary hemangiomatosis (PCH) is frequently present within 
the lungs of PVOD patients. PCH is comprised of regions of alveolar hypercellularity 
that reflect increased numbers of capillary endothelial cells.[6,9,17] In addition to the 
alveolar distribution, foci of PCH may infiltrate into the wall of small conducting 
airways and into the walls of pulmonary veins, contributing to the occlusive process 
in some cases of PVOD. Pulmonary arterial medial hypertrophy and intimal fibrosis 
are also common findings within PVOD lung. In part because of the frequency of PA 
lesions in PVOD, both PVOD and PCH have been classified together as a subgroup 
of PAH in the most recent clinical classification of PH in humans.[38] 
In veterinary medicine, there remains a poor understanding of the breadth of causes 
of pulmonary hypertension and the spectrum of vascular remodeling associated with 
the disease.[16] Unlike in human medicine, pulmonary arterial catheterization is 
rarely performed to measure PA pressures in dogs; instead, such pressures are 
estimated using Doppler echocardiography to measure tricuspid valve regurgitation 
velocity as a proxy for direct measurement of PA pressures.[13,29,35,36] PAH is 
most often recognized in dogs as a sequela to congestive heart failure and PVH in 
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small breed dogs with chronic mitral valve disease, secondary to heartworm 
infection, or associated with chronic interstitial lung disease.[15,34,39,41] Idiopathic 
PAH (iPAH) is recognized clinically in dogs. A study of 6 dogs clinically diagnosed 
with iPAH48 identified histologic PA changes similar to those in human iPAH, 
including arterial medial hypertrophy and intimal thickening, with rare plexiform 
lesions.[48] PH developing as a result of non-cardiogenic pulmonary venous 
hypertension has not been described in non-human animals. 
Herein we describe the gross and histologic findings in 11 dogs that died from 
primary pulmonary disease, with similar lesions as PVOD in humans. 
 
Materials and Methods 
Tissue Collection and Preparation 
 Samples of lung were collected from 11 dogs that were euthanized for 
progressive respiratory disease. Sections of lung were fixed in 10% neutral buffered 
formalin and routinely processed, sectioned at 6 µm, and stained with hematoxylin 
and eosin (HE) and Verhoeff van Gieson (VVG). Histologic sections and 
immunohistochemistry together were evaluated by one author (K. Williams). 
 
Transmission Electron Microscopy 
 Formalin-fixed lung from a single case of PVOD (dog No. 1) was rinsed in 0.1 
mol/L phosphate buffer, placed in osmium tetroxide (Electron Microscopy Sciences; 
Fort Washington, PA, USA) for 3 hours, rinsed again in 0.1 M phosphate buffer, 
rinsed 3 times in 30% ethanol for 10 minutes each, transferred into 2% uranyl 
acetate (Electron Microscopy Sciences) for 1 hour, rinsed in 30% ethanol, and 
dehydrated in a graded series of ethanol. The tissues were placed in propylene 
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oxide before being embedded in DMP-30 and araldite 501 (Electron Microscopy 
Sciences). One-µm sections were cut on an LKB microtome and stained with 
Toluidine blue. Tissues of interest were sectioned at 600 angstroms, stained with 
uranyl acetate and lead citrate and examined on a Phillips 301 electron microscope 
(Phillips; Atlanta, GA, USA). 
 
Immunohistochemistry 
 Immunohistochemical labeling was performed on sections of lung from dogs 
No. 1, 2, 3, 4, 8, 9, 10, and 11 at the Diagnostic Center for Population and Animal 
Health at Michigan State University. The cases included for immunohistochemistry 
originated in the United Kingdom (dog No. 1), Michigan (dogs No. 2, 3, 4, 9, 10, 11), 
and Massachusetts (dog No. 8). Briefly, representative sections of lung were 
incubated with primary antibodies directed against CD204 for macrophage/dendritic 
cells (Trans Genic Inc, Kumamoto, Japan; mouse monoclonal 1:1000), CD3 for T 
cells (Dako, Carpinteria, CA, USA; rabbit polyclonal, 1:200), CD20 for B cells 
(Neomarkers Thermo-Scientific, San Jose, CA, USA; rabbit polyclonal, 1:500), αSMA 
(Dako; mouse monoclonal 1:50), desmin (Dako; mouse monoclonal, 1:400), and 
CD31 for endothelial cells (Dako; mouse monclonal, 1:50). The process was 
performed using the Bond Max Automated Staining system with the Bond Polymer 
Detection system (Vision Biosystems, Leica, Bannockburn, IL, USA) using 3,3’-
diaminobenzadine as the chromogen with hematoxylin counterstain. Phosphate-
buffered saline was substituted for the primary antibody as the negative control. 
Normal lung from a dog that died of non-pulmonary disease served as a control for 
comparison. 
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Results 
Clinical Findings 
The 11 dogs included in this study represent cases from Michigan (7 dogs), 
Massachusetts (1 dog), California (2 dogs), and the United Kingdom (1 dog). The 
average age was 10.5 years, and there were 5 males and 6 females (Supplemental 
Table 1). Breeds represented included mixed breed (2), Golden Retriever (2), 
Australian Shepherd (2), and a single Greyhound, German Shepherd, Beagle, 
Border Collie, and Labrador Retriever. Presenting signs included acute onset of 
respiratory distress (9), cough (4), inappetence (4), abdominal distension (1), and 
progressive lethargy leading to collapse (1). Duration of clinical signs prior to 
presentation ranged from 1 to 21 days in 6 dogs; this information was not available in 
the remaining 5 cases. Chest radiographs performed in 5 dogs showed a mixed 
bronchial and diffuse heavy interstitial pattern most prominent in the caudodorsal 
lung fields. Additional radiographic findings included focal areas of alveolar disease 
(4) and pulmonary arterial enlargement (4). Arterial blood gas composition was 
analyzed in 2 dogs and showed respiratory alkalosis with severe hypoxemia. 
Echocardiography with Doppler was performed in 3 dogs (dog Nos. 2, 6, and 7) and 
showed significant pulmonary arterial hypertension (gradients of 88, 52, and 89 mm 
Hg, respectively; normal ≈25 mm Hg). Five dogs were euthanized within hours of 
presentation due to rapidly deteriorating condition. The remaining animals survived a 
variable amount of time, no longer than 6 months post-presentation, before being 
euthanized. 
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Gross Pathology 
 Significant gross lesions were restricted to the lungs. The lungs in PVOD dogs 
were diffusely moderately edematous and consolidated with a “meaty” consistency. 
Throughout the lungs were widespread, often discrete, foci of congestion (Fig. 1). On 
cut section, these foci extended well into the alveolar parenchyma and had relatively 
sharp borders delimiting the edge from the surrounding more normal parenchyma 
(Fig. 2). There was no gross evidence of pneumonia and no exudate in the 
examined airways. No gross evidence of underlying cardiac disease was 
documented in any of the dogs; compensatory hypertrophy of the right ventricle was 
noted grossly in 2 dogs. 
 
Histopathology 
In evaluating lungs where PVOD is suspected, it is essential to definitively 
distinguish between arteries and veins. In the current study, veins were identified 
using a combination of histologic features, anatomic localization, and Verhoeff-van 
Gieson staining to identify elastic laminae. Pulmonary veins were distinguished by 
their relatively thin tunica media and single external elastic lamina (Fig. 3); similarly 
sized pulmonary arteries had a thicker tunica media and internal and external elastic 
laminae (not shown). In addition, the small pulmonary veins most frequently affected 
in canine PVOD were isolated within the alveolar parenchyma, whereas most 
branches of similarly sized pulmonary arteries are associated with a conducting 
airway. 
The main histologic findings (Fig. 4, Supplemental Table 2) consisted of 
venous remodeling with or without arterial remodeling, segmental congestion of 
alveolar capillaries, foci of PCH, and increased numbers of alveolar macrophages 
 9 
that frequently contained cytoplasmic hemosiderin. Occasional small foci of acute 
alveolar injury with fibrin exudation and hyaline membrane formation were noted in 
some of the dogs. 
The venous remodeling in canine PVOD (11/11 dogs) mostly affected post-
capillary venules and small (up to approximately 300 µm) intra-parenchymal veins. 
Not all pulmonary veins and venules examined were affected; some regions of the 
lung had few abnormal veins. The lumen of affected veins was partially to completely 
occluded by densely to loosely organized collagen, and there were numerous plump 
spindle cells within the intima (Fig. 5). When the venous lumen was evident, it was 
markedly reduced and tortuous. In small numbers of veins, well-organized bundles of 
smooth muscle cells were arranged parallel with the long axis of the vessel (Fig. 6). 
In a single dog (No. 5), the occlusive process developed primarily through the 
infiltration of vein walls with numerous small capillaries (Fig. 7). This case also had 
very large thin-walled dilated vascular structures without evident elastic lamina 
present around medium-sized pulmonary veins (not shown). In the most severely 
affected vessels, veins were replaced by collagen, and their identity could only be 
determined in the VVG-stained sections (not shown). 
Foci of PCH were found in 11 of 11 cases. The affected alveoli were often 
localized around remodeled veins (Fig. 4); the hypercellularity of alveolar septa 
appeared to result from increased numbers of plump endothelial cells (Fig. 8). 
Frequently the foci of PCH were associated with segmental congestion of alveolar 
capillaries. In many cases, capillary profiles were evident within the wall of 
respiratory bronchioles, where they infiltrated around the smooth muscle bundles 
and beneath the luminal epithelium (Fig. 9) as well as within the walls of pulmonary 
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veins. PCH was the main histologic finding in 2 dogs; in these cases, veno-occlusive 
remodeling of post-capillary venules was identified in the VVG-stained sections. 
Pulmonary arterial remodeling was a significant finding within the lungs of 6 of 
11 PVOD dogs (Supplemental Table 2). As with the venous disease, smaller 
pulmonary arteries were more commonly affected. The arterial lesions differed from 
those present in the veins, consisting of eccentric to concentric intimal expansion by 
increased extracellular matrix and moderate to marked medial hypertrophy. 
 
Vein Ultrastructure 
 Transmission electron microscopy (TEM) was performed on a single case 
(dog No. 1). The intima of pulmonary veins was expanded by numerous smooth 
muscle cells and collagen (Figs. 10, 11). 
 
Immunohistochemistry 
 In normal canine lung, expression of αSMA and desmin was evident within the 
smooth muscle cells of the tunica media of arteries and veins (Fig. 12); there was 
greater intensity of labeling for αSMA than desmin in these cells. Importantly, there 
was little expression of either of these proteins within the normal canine alveolar 
septum (Fig. 12). In cases of PVOD, the spindle cell component within the intima of 
the remodeled veins labeled intensely with antibodies against αSMA (Supplemental 
Figs. 1–2); desmin expression was also present, though less prominent than αSMA 
(not shown). αSMA immunolabeling highlighted the well-organized bundles of 
smooth muscle cells running parallel with the long axis of the veins as noted 
previously (Fig. 6, Supplemental Fig. 2). There was marked expression of αSMA 
within spindle cells in the alveolar septa in the PVOD lung. This expression was 
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especially prominent within the foci of PCH (Supplemental Figs. 1–3) but also was 
increased within non-PCH alveoli compared to the control lung (Supplemental Fig. 
3). Similar though less intense expression of desmin was also detected in these 
areas of the alveolar septa (not shown). 
CD31 expression in normal canine lung was restricted to the plasma 
membrane of endothelial cells of arteries, veins, and capillaries (Supplemental Fig. 
4). In PVOD, the expression of CD31 was markedly increased within the foci of PCH 
(Supplemental Fig. 5a) and also highlighted the endothelial cells lining the reduced 
lumen of remodeled veins (Supplemental Fig. 5b). In the dogs with capillary 
infiltration into pulmonary veins and airways, CD31-positive endothelial cells lined 
these vascular spaces (not shown). 
Immunohistochemistry for CD20 identified small numbers of B cells within 
PVOD lung (not shown). There was no apparent pattern to their distribution and no 
association between these cells and the remodeled veins or foci of PCH. CD3-
positive T cells were present scattered throughout the PVOD lungs. In addition, 
some remodeled veins had small numbers of CD3-positive cells at the periphery of 
the remodeled vessel as well as within the venous wall (Supplemental Fig. 6). 
Immunohistochemistry for CD204 identified macrophages throughout the PVOD 
lung, but this was not co-localized with the remodeled vasculature (data not shown). 
There was no labeling of the lung in the negative control slides for any of the 
antibodies.  
 
Discussion 
Pulmonary veno-occlusive disease was first reported in human medicine in 
1934 after a 48-year-old baker in Germany died from a progressive respiratory 
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disease characterized by dyspnea, pulmonary edema, and cyanosis.11 It wasn’t until 
approximately 40 years after this initial description that PVOD was classified as a 
distinct and serious form of PH in humans.[8] Herein we provide the first description 
of a condition in adult dogs that shares the pathology and many clinical features with 
PVOD in people. Affected dogs experienced respiratory distress, which, based on 
our small cohort of cases, appears to be associated with severe PAH. The lung 
changes consist of severe and widely distributed veno-occlusive remodeling 
affecting post-capillary venules and small veins; this venous remodeling is, in part, 
characterized by smooth muscle cells occluding the vascular lumen. In addition, 
most dogs had alveolar foci consistent with PCH as well as remodeling of pulmonary 
arteries. Based on our findings, lung vascular remodeling with lesions similar to 
PVOD in humans occurs in dogs. The cause(s) of the vascular disease remains 
unknown. 
The clinical presentation of PVOD in this series of dogs suggests that in most 
instances this is a rapidly progressive and severe disease leading to death or 
euthanasia. In people with PVOD, the clinical presentation is usually reported to be 
more gradual and initially is indistinguishable from other causes of PAH.[19,21] 
Rarely, human patients with PVOD experience hemoptysis as well as rapid decline 
and death that is more similar to the canine disease.[17] In canine PVOD, the 
disease has thus far only been documented in adults (mean age = 10.5 years) while 
in humans there is more variability in the age of affected individuals. Most studies of 
PVOD in people suggest that it is more prevalent in children and young adults, 
although there are well-documented cases developing in older 
individuals.[10,12,19,47] With the recognition of PVOD in dogs, it will be important to 
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carefully assess the lungs of younger animals for similar pulmonary vascular 
pathology. 
PVOD in humans is considered to be a rare form of severe PH, with an estimated 
incidence of approximately 10% of unexplained PH cases, or .1 to .2 cases per 
million individuals.[38] The incidence of PVOD in dogs is not known, but there is 
reason to think that it may be higher in the canine population than in people. Given 
that this is the first report of PVOD in dogs, it seems reasonable to assume that a 
significant number of cases may be unrecognized or misdiagnosed. Substantiating 
this assertion, 2 of the dogs in this study were initially diagnosed by pathologists as 
having chronic congestive heart failure based on the presence of hemosiderophages 
in the lung. More work is necessary to define the clinical presentation to facilitate 
prospective identification of cases and to aid in the clinical management of canine 
PVOD. It will be especially important to document PA pressures when possible in 
affected animals to expand our understanding of the pulmonary pathophysiology in 
canine PVOD. 
Histopathology has played an important role in classifying phenotypes of human 
PAH.[38] Pulmonary arterial hypertension, regardless of the underlying cause and 
pathogenesis, is histologically characterized primarily by arterial medial hypertrophy 
(especially at the level of pre-capillary arterioles) and varying degrees of intimal 
fibrosis.[6,27] Complex lesions are typified by the development of plexiform 
arteriopathy, which consists of foci of arterial mural destruction and the development 
of associated perivascular endothelium-lined channels. These complex lesions are 
less common than the aforementioned primary lesions and associated with more 
severe clinical disease.[27,28] Importantly for the purposes of this study, venous 
remodeling is not a feature of iPH in humans, although arterial remodeling is often 
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noted in human PVOD.[6,45] In the latest clinical classification of PH in humans, 
PVOD and PCH are placed within their own subgroup of PAH based in part on the 
frequency of PA remodeling in these diseases.[3,38] As in human PVOD, pulmonary 
arterial medial hypertrophy and intimal thickening were relatively common in small- 
to medium-sized PA in canine PVOD. The arterial changes in PVOD are assumed to 
be the result of increased arterial pressures that develop secondary to the 
downstream venous lesions.[45] This mechanism is unproven, and there are some 
who consider the venous and arterial lesions to reflect a continuum of vascular 
pathology affecting vessels on both sides of the capillary bed.[17] 
Efforts to classify PH in veterinary species, beyond documenting the clinical and 
hemodynamic features of PH, are lacking to date, and there is scant information 
correlating pulmonary vascular lesions with severity of clinical disease in veterinary 
medicine. Although PH is well recognized clinically in dogs, there is little information 
describing the pulmonary vascular histopathological changes of such patients. A 
retrospective study described the pulmonary arterial pathology in 6 dogs that were 
clinically classified as idiopathic pulmonary hypertension. The most frequent lesions 
were PA medial hypertrophy and intimal thickening as well as occasional complex 
lesions.[48] As described in human PH patients, in this small group of dogs, the 
presence of complex lesions was associated with more severe clinical disease; 
venous pathology was not noted in this study.[48] 
The histopathology of canine PVOD is very similar to the human disease and is 
central to definitively identifying the disease. In both canine and human PVOD, the 
diagnostic hallmark is the widespread remodeling of small- to medium-sized 
pulmonary veins. In human PVOD, remodeling of pre-septal venules is characteristic 
and a necessary finding to make the histologic diagnosis.[6] In canine PVOD, small- 
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to medium-sized intra-parenchymal branches of pulmonary veins were the most 
commonly affected vessels. While the venous remodeling was widespread within 
individual sections of the lung, normal veins could still be detected, and in some lung 
regions most examined veins were essentially normal. This finding is consistent with 
reports of human PVOD where 10% to 90% of veins had histologic features 
diagnostic of the disease.[17,44] Therefore, in suspect cases of PVOD, it is 
important that the pathologist collect and histologically examine multiple sections 
from both lungs to maximize the opportunity to identify the characteristic vascular 
lesions. 
The occlusive remodeling in pulmonary veins of canine PVOD is primarily the result 
of bundles of smooth muscle cells, although in an individual dog, the venous 
occlusion was the result of an apparent in-growth of capillary profiles. The identity of 
smooth muscle cells was confirmed through the use of αSMA and desmin 
immunohistochemical labeling as well as TEM on veins from a single PVOD dog. 
Similarly, in human PVOD, αSMA-positive cells can be found as a component of the 
vascular remodeling in the disease.[6,45] The origin of the smooth muscle cells in 
the remodeled veins is unknown in either the human or canine disease. Initial reports 
in human medicine suggest they migrate into the vasculature from the tunica 
media,[45] although this remains speculative at this time. Myofibroblasts also 
express αSMA and can express desmin and could be considered as an alternative 
cell contributing to the occlusive process, although the morphology of the cells in 
PVOD-affected veins makes this less likely. Studies in a hypoxia-induced model of 
PAH in mice have determined that the smooth muscle cells in the distal arterioles 
originate from preexisting smooth muscle cells rather than from other cell types such 
as myofibroblasts or pericytes.[37] 
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Foci of pulmonary capillary hemangiomatosis—regions of alveolar hypercellularity 
determined to be proliferative capillaries—were the second most common finding 
within the lungs of canine PVOD. PCH in canine PVOD was present mostly within 
the alveoli but also surrounded and infiltrated into the walls of conducting airways, 
small veins, and venules; this distribution is similar to what is reported for PCH in 
human PVOD.[9,17] Immunohistochemistry demonstrated increased CD31, αSMA, 
and desmin labeling in foci of PCH, suggesting expansion of both endothelial cell 
and contractile interstitial cell populations. CD31 immunolabeling also confirmed the 
phenotype of capillary profiles within airway and vessel walls in the canine lung 
affected by PVOD and PCH. The ability of capillary endothelial cells in PCH to 
proliferate and infiltrate into airways and blood vessels initially led investigators to 
suggest that PCH is a low-grade vascular neoplasm. However, because there is no 
evidence of clonality and the cells are cytologically bland, PCH is no longer 
considered a neoplasm.[25] 
As noted previously, PVOD and PCH have been grouped together in the most recent 
clinical classification of PH in people,[38] although there is an ongoing discussion as 
to whether or not PVOD and PCH are 2 distinct diseases. The largest study to 
address this question examined 35 cases of PVOD and 5 of PCH and detected PCH 
in 73% of PVOD cases, leading the authors to conclude that most cases of PCH 
likely reflect underlying unrecognized PVOD.17 In our study, all PVOD dogs had foci 
of PCH; in 2 cases, PCH was the predominant finding, and it was only after 
evaluation of VVG-stained lung that remodeled veins were identified. Therefore, the 
findings in these cases of canine PVOD are in agreement with the contention in 
human medicine that PVOD underpins the development of PCH.[17] 
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Within canine PVOD lung, there was marked widespread distribution of αSMA- and 
desmin-expressing spindle cells in the alveolar septa that was especially prominent 
in areas of PCH. Similar cells expressing these proteins could only be found isolated 
in the interstitium between adjoining alveoli in normal canine lung. The cell 
morphology and location of these cells suggests that they could be interstitial 
myofibroblasts or pericytes. Pericytes are specialized mesenchymal cells closely 
apposed to endothelial cells in the microvasculature,5 while myofibroblasts are 
αSMA-expressing spindle cells that can be induced in the lung under a variety of 
disease states, including pulmonary hypertension.14 Pericytes are well known to 
play a role in vasoproliferative processes,[1,2,5] thus the co-localization of these 
cells in the foci of PCH suggests this may represent pericyte upregulation in support 
of capillary endothelial cell proliferation in the foci of PCH. The mechanism(s) for the 
induction of these cells—whatever their phenotype—within the alveolar septa may 
be in response to elevated vascular pressures within the capillary bed. αSMA-
positive, desmin-negative spindle cells were identified as myofibroblasts in the lungs 
of human patients with post-capillary PH (including PVOD patients) but not in those 
with pre-capillary PH, suggesting that such cells are induced by the mechanical 
stretch caused by capillary congestion in post-capillary PH.[14] 
The cause(s) of canine PVOD is not known. Venous remodeling similar to that seen 
in PVOD has been noted in diseases that would be expected to lead to increased 
pulmonary venous pressures, including mitral valve stenosis and fibrosing 
mediastinitis in humans and in the lungs of horses experiencing severe exercise-
induced pulmonary hemorrhage.[3,46] No coincidental left-sided cardiovascular 
disease was identified in the dogs in this study, suggesting that canine PVOD is not 
the result of sustained elevation in left atrial pressure. 
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It is possible that the vascular remodeling in canine PVOD is a common endpoint 
from a variety of possible causes. Potential causes suggested for human PVOD 
include genetic factors, exposure to toxins (especially alkylating chemotherapeutic 
agents), viral infections, and immune-mediated mechanisms.[19,31] A genetic basis 
has been documented in familial forms of the human disease. Mutations in the bone 
morphogenetic protein-2 receptor are associated with up to 50% of familial forms of 
PAH and have been identified in a small subset of human PVOD.[4,32] More 
recently, 13 families in France with a history of PVOD in at least 1 family member 
were determined to have mutations in the gene encoding the serine-threonine kinase 
EIF2AK4.[7] The lack of an apparent breed predilection for canine PVOD in our 
study does not suggest a genetic basis for the canine disease at this time. 
Inflammatory and immune mechanisms are increasingly implicated in the 
pathogenesis of PAH,[30,40] though their role in PVOD is not known. PVOD patients 
but not PAH patients had decreased numbers of circulating cytotoxic lymphocytes 
and natural killer T cells and increased numbers of natural killer cells within their 
peripheral blood.[26] In addition, the amount of granulysin in these cells was 
decreased while free serum granulysin levels were increased, suggesting immune 
dysregulation as a factor in the pathogenesis of human PVOD.[26] As a first step 
toward investigating a role for immune mechanisms in canine PVOD, we utilized 
immunohistochemical labeling to look for co-localization of T cells, B cells, and 
macrophage/dendritic cells with the remodeled vasculature in canine PVOD. There 
was no evidence for such a relationship for B cells and macrophage/dendritic cells, 
but there were small numbers of T cells surrounding and within the wall of occasional 
remodeled veins. This limited study does not prove a role for T cells in the 
pathogenesis of canine PVOD but does warrant additional investigation. 
 19 
Animal models to investigate the biology of PVOD had not been developed until 
recently. The transcription factor Erg is involved in a number of functions related to 
blood vessel formation and binds to the gene Aplnr, which is known to be expressed 
in venous endothelium.[23,33] Recently, a murine model of PVOD was developed by 
homozygous deletion of Erg.[18] Homozygotes died between embryonic day 16.5 
and 3 months of age with severe pulmonary venous occlusion.[18] Furthermore, 
lungs from PVOD patients had decreased levels of Erg and Aplnr, suggesting that 
this pathway may provide a point of disruption in cell signaling within veins that can 
play a role in the development of PVOD.[18] Canine PVOD may provide a 
spontaneous model to investigate this and other potential pathways important in the 
development of the veno-occlusive remodeling in PVOD. 
In summary, we have identified a form of pulmonary vascular remodeling in dogs 
with pathology similar to PVOD in humans. The lung lesions are comprised of severe 
and widely distributed veno-occlusive remodeling affecting post-capillary venules 
and small veins that was, in part, the result of smooth muscle cells and collagen 
occluding the vascular lumen. In addition, all dogs had foci consistent with PCH, as 
well as remodeling of pulmonary arteries, and numerous alveolar 
hemosiderophages. The cause and pathogenesis of this disease remain to be 
determined.  
Article notes 
Supplemental material for this article is available on the Veterinary Pathology 
website at http://vet.sagepub.com/supplemental.  
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Figure legends 
Figure 1. Pulmonary veno-occlusive disease, lung; dog No. 4. The lungs are diffusely consolidated with edema 
and widespread foci of congestion.  
Figure 2. Pulmonary veno-occlusive disease, formalin-fixed lung, dog No. 1. The regions of alveolar congestion 
are sharply demarcated (arrows) from more normal lung.  
Figure 3. Normal pulmonary vein, dog. (a) The pulmonary vein (V) has a thin tunica media relative to the vessel 
diameter. Hematoxylin and eosin (HE). (b) There is an external elastic lamina at the periphery of the vessel wall 
(external elastic lamina, arrow) but no internal elastic lamina. Verhoeff van Gieson (VVG). 
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Figure 4. Pulmonary veno-occlusive disease, lung; dog No. 1. There is venous remodeling (V), segmental 
alveolar capillary congestion (arrow), foci of pulmonary capillary hemangiomatosis (PCH) (arrowheads), and 
increased numbers of alveolar macrophages. Hematoxylin and eosin (HE).  
Figure 5. Pulmonary veno-occlusive disease, lung, dog No. 1. (a) Remodeling of a pulmonary vein. The lumen (L) 
of a severely remodeled vein is difficult to visualize. Inset: pulmonary capillary hemangiomatosis in the alveoli 
adjacent to the aforementioned venous remodeling. HE. (b) The identity of the vessel as a vein was confirmed by 
the presence of a single external elastic lamina (EEL, arrow). Note the tortuous lumen of the vein extending to 
the lower left. Verhoeff van Gieson (VVG).  
Figure 6. Pulmonary veno-occlusive disease, lung; dog No. 8. Remodeling has completely occluded a pulmonary 
vein, without a significant increase in thickness of the tunica media (arrow). Note the markedly engorged 
capillaries surrounding the remodeled vein. HE.  
Figure 7. Pulmonary veno-occlusive disease, lung; dog No. 5. (a) The venous remodeling is characterized by 
infiltration of the vein (V) wall by numerous capillary profiles (C). HE. (b) The identity of the vein is confirmed by 
the presence of the external elastic lamina at the periphery of the tangle of vessels (EEL, arrow). VVG. 
 
 25 
Figures 8–9. Pulmonary capillary hemangiomatosis (PCH), lung, dog No. 7. Hematoxylin and eosin (HE).  
Figure 8. The alveoli in this focus of PCH are hypercellular due to increased numbers of plump endothelial cells 
(arrow).  
Figure 9. Foci of proliferative capillary profiles often extend into the walls of respiratory bronchioles (rBr), where 
the vessels surround smooth muscle bundles and extend beneath the epithelium (arrow). Inset: capillary profiles 
surround the bronchiolar smooth muscle bundle.  
Figure 10. Pulmonary veno-occlusive disease, lung; dog No. 1. In the remodeled pulmonary vein, the lumen (L) is 
markedly reduced due to proliferation of plump spindle cells within the intima. External elastic lamina (arrow). 
Toluidine blue, plastic-embedded section.  
Figure 11. Pulmonary veno-occlusive disease, lung; dog No. 1. An intimal population of spindle cells extends into 
the lumen (L) of an affected remodeled vein. Inset: There are numerous microfilaments (arrow) within the 
cytoplasm of the spindle cell population consistent with smooth muscle cells. Transmission electron microscopy.  
Figure 12. Normal lung, dog. The tunica media of normal canine pulmonary veins express both (a) α-smooth 
muscle actin (αSMA) and (b) desmin. There is little expression of αSMA or desmin within the surrounding 
alveolar septa. Insets: smooth muscle labeling. Immunohistochemistry (IHC) for (a) αSMA and (b) desmin.
 
